# A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors

> **NCT07231211** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Shengdi Pharmaceutical Co., Ltd** · enrollment: 258 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** SHR-4610 Injection

## Key facts

- **NCT ID:** NCT07231211
- **Lead sponsor:** Shanghai Shengdi Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-20
- **Primary completion:** 2026-10
- **Final completion:** 2027-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07231211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07231211, "A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07231211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*